508 related articles for article (PubMed ID: 10579246)
1. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial.
Corwin HL; Gettinger A; Rodriguez RM; Pearl RG; Gubler KD; Enny C; Colton T; Corwin MJ
Crit Care Med; 1999 Nov; 27(11):2346-50. PubMed ID: 10579246
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial.
Corwin HL; Gettinger A; Pearl RG; Fink MP; Levy MM; Shapiro MJ; Corwin MJ; Colton T;
JAMA; 2002 Dec; 288(22):2827-35. PubMed ID: 12472324
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317].
Georgopoulos D; Matamis D; Routsi C; Michalopoulos A; Maggina N; Dimopoulos G; Zakynthinos E; Nakos G; Thomopoulos G; Mandragos K; Maniatis A;
Crit Care; 2005 Oct; 9(5):R508-15. PubMed ID: 16277712
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of epoetin alfa in critically ill patients.
Corwin HL; Gettinger A; Fabian TC; May A; Pearl RG; Heard S; An R; Bowers PJ; Burton P; Klausner MA; Corwin MJ;
N Engl J Med; 2007 Sep; 357(10):965-76. PubMed ID: 17804841
[TBL] [Abstract][Full Text] [Related]
6. Prospective randomized double-blind placebo controlled trial of recombinant human erythropoietin administration to reduce blood transfusions in anemic pediatric intensive care patients.
Chicella MF; Krueger KP
J Pediatr Pharmacol Ther; 2006 Apr; 11(2):101-6. PubMed ID: 23118648
[TBL] [Abstract][Full Text] [Related]
7. Alternatives to blood product transfusion in the critically ill: erythropoietin.
Stubbs JR
Crit Care Med; 2006 May; 34(5 Suppl):S160-9. PubMed ID: 16617261
[TBL] [Abstract][Full Text] [Related]
8. Anemia and blood transfusion in the critically ill patient: role of erythropoietin.
Corwin HL
Crit Care; 2004; 8 Suppl 2():S42-4. PubMed ID: 15196323
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients.
MacLaren R; Sullivan PW
Value Health; 2005; 8(2):105-16. PubMed ID: 15804319
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.
Case DC; Bukowski RM; Carey RW; Fishkin EH; Henry DH; Jacobson RJ; Jones SE; Keller AM; Kugler JW; Nichols CR
J Natl Cancer Inst; 1993 May; 85(10):801-6. PubMed ID: 8487324
[TBL] [Abstract][Full Text] [Related]
11. A controlled trial of recombinant human erythropoietin after bone marrow transplantation.
Link H; Boogaerts MA; Fauser AA; Slavin S; Reiffers J; Gorin NC; Carella AM; Mandelli F; Burdach S; Ferrant A
Blood; 1994 Nov; 84(10):3327-35. PubMed ID: 7949088
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
Henry DH; Abels RI
Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
[TBL] [Abstract][Full Text] [Related]
14. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
Voils SA; Harpe SH; Brophy GM
Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
[TBL] [Abstract][Full Text] [Related]
15. Benefits and harms of red blood cell transfusions in patients with septic shock in the intensive care unit.
Holst LB
Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836806
[TBL] [Abstract][Full Text] [Related]
16. The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States.
Corwin HL; Gettinger A; Pearl RG; Fink MP; Levy MM; Abraham E; MacIntyre NR; Shabot MM; Duh MS; Shapiro MJ
Crit Care Med; 2004 Jan; 32(1):39-52. PubMed ID: 14707558
[TBL] [Abstract][Full Text] [Related]
17. Use of exogenous erythropoietin in critically ill patients.
MacLaren R; Gasper J; Jung R; Vandivier RW
J Clin Pharm Ther; 2004 Jun; 29(3):195-208. PubMed ID: 15153081
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation in elective surgery with large blood needs (> or = 5 units): a randomized study.
de Pree C; Mermillod B; Hoffmeyer P; Beris P
Transfusion; 1997 Jul; 37(7):708-14. PubMed ID: 9225934
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human erythropoietin use in intensive care.
Darveau M; Notebaert E; Denault AY; Bélisle S
Ann Pharmacother; 2002 Jun; 36(6):1068-74. PubMed ID: 12022910
[TBL] [Abstract][Full Text] [Related]
20. The role of erythropoietin therapy in the critically ill.
Corwin HL
Transfus Med Rev; 2006 Jan; 20(1):27-33. PubMed ID: 16373185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
